Itolizumab not checked

Biocon Limited · EQ001 · Bmab600

FollowEvery change as it happens, and a Monday email
Stage
No active trials
 
Next date
None yet
 
Trials
0 active
6 in total · 1 in the EU
Targets
—
None known yet

What this is

How it works
An antibody: a lab-made immune protein built to latch onto one target in the body.-mab: monoclonal antibodies WHO name stem
How it’s given
“First dose of 1.6 mg/kg dose iv infusion, , investigator discretion to continue with 1.6 mg/kg dose every 2 weeks or 0.8 mg/kg weekly regimen up to 4 weeks. BSC: similar to Arm B”In the company’s words, NCT04475588 on ClinicalTrials.gov
Tested for
GVHD (2 trials), Acute-graft-versus-host Disease (2 trials), aGVHD (2 trials), Coronavirus, Graft Versus Host Disease, Acute GVHD, Acute Respiratory Distress Syndrome, Cytokine Release Syndrome and 5 more
Main trialPhase 3
“This is a randomized controlled trial to evaluate the efficacy and safety of itolizumab in subjects hospitalized with COVID-19.”In the company’s words, NCT04605926 on ClinicalTrials.gov
Other names
EQ001 · Bmab600

Other drugs for GVHD

All 24 drugs for GVHD

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials6

TrialPhaseCompletesWhat it tests
Phase 3Withdrawn Apr 2021 A Study to Evaluate the Efficacy and Safety of Itolizumab in Subjects Hospitalized With COVID-19
Phase 3Terminated 22 Apr 2025 A Study of Itolizumab in Combination With Corticosteroids for the First-Line Treatment of Acute Graft Versus Host Disease (EQUATOR)
Phase 2Completed 7 Jul 2020 Efficacy and Safety of Itolizumab in COVID-19 Complications
Phase 1/2Completed 21 Nov 2022 A Study to Evaluate the Safety, Tolerability, PK, PD, and Clinical Activity of EQ001 in Subjects With aGVHD
Phase 1Completed 12 Oct 2021 A Study of Itolizumab (EQ001) to Evaluate the Safety, Tolerability, PK, PD, and Clinical Activity in Uncontrolled Asthma
Phase 1Completed 16 Nov 2023 Study of EQ001 (Itolizumab) in Systemic Lupus Erythematosus With or Without Active Proliferative Nephritis
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow Itolizumab

Following is part of Solo: you see every change to Itolizumab the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in